ArticleScientific data2025
PROTAC-PatentDB: A PROTAC Patent Compound Dataset.
Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mapping Scientific Landscapes and Therapeutic Innovations of Targeted Protein Degradation: A Scientometric Review.Pharmaceutics · 2026Review
- AI-assisted design and virtual profiling of targeted degraders for pancreatic cancer therapy via PROTAC technology.American journal of cancer research · 2026Article
- PROTAC-PatentDB: A PROTAC Patent Compound Dataset.Scientific data · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Proteolysis-targeting chimeras (PROTAC) are emerging and promising molecules for targeted protein degradation which have the potential to overcome critical bottlenecks in traditional small molecule drug development. However, the scarcity of publicly available data on molecular compound structures has significantly hindered computational drug discovery and AI-aided drug discovery/design (AIDD) in this field. Patents are an important but underutilized source of novel chemical structures in medicinal chemistry. In this study, we collected PROTAC patents published in 2013-2023 and the associated chemical structures disclosed therein. Through manual screening and expert curation, we identified 63,136 unique PROTAC compounds under 590 patent families, along with 252 targets. Additionally, we employed the ADMETlab 3.0 platform to predict 120 physicochemical properties for all compounds. The dataset is publicly available on the Figshare platform, and an online webserver ( http://protacpatentdb.com ) has also been established. Given the rapid growth of PROTAC patent literature, this dataset can be further expanded as new patents are continuously published.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.